A review in Naunyn-Schmiedeberg's Archives of Pharmacology, published ahead of print Thursday ↗, pulls together the case that a designed peptide called FOXO4-DRI selectively kills worn-out cells in the aging brain. In aged mouse models of Alzheimer's, amyloid-β and pathological tau cleared along with the cells.
What a senolytic is, in one paragraph
Older cells accumulate damage and stop dividing. Most die off. A fraction do not. They stay alive, stop doing their day jobs, and start leaking inflammatory signals. Biologists call this state cellular senescence. The inflammatory output has its own acronym (SASP, the senescence-associated secretory phenotype) and a real role in the biology of aging. A senolytic drug is one that selectively kills senescent cells without harming healthy ones. Clear the senescent cells, the theory goes, and the tissue calms down.
What FOXO4-DRI does
FOXO4-DRI is a designed peptide that disrupts a specific protein interaction inside senescent cells. In these cells, the FOXO4 transcription factor binds p53 (a tumor suppressor) and keeps the cell alive by suppressing p53's apoptosis program. FOXO4-DRI breaks that complex. p53 is released. The cell dies.
"DRI" stands for D-retro-inverso. That is a chemistry trick: take the peptide's sequence, reverse it, and swap every amino acid for its mirror-image (D-) version. The result has a similar three-dimensional shape to the natural L-peptide but resists most proteases. Retro-inverso design is how peptide drugs survive long enough in the body to work without injection-grade formulation gymnastics.
What it did in aged mice
Per the review, FOXO4-DRI administered to aged mammalian models reduced the accumulation of senescent cells, restored cerebral blood flow, restored the integrity of the blood-brain barrier, reversed hippocampal atrophy (the hippocampus shrinks in normal aging and in Alzheimer's), and improved cognitive function on standard tests.
In mouse models of Alzheimer's disease and tauopathy specifically, FOXO4-DRI also eliminated amyloid-β and pathological tau. That connection is the story. Amyloid and tau are the two proteins Alzheimer's therapies have spent twenty years trying to clear. A senolytic peptide may be clearing them indirectly, by killing the senescent cells that generate them or fail to clear them.
This builds on our coverage earlier this week ↗ of the Phase 3 semaglutide substudy showing tau biomarker reduction in cerebrospinal fluid. Two very different peptide classes, a GLP-1 agonist and a senolytic, both landing on the same pathological marker.
Where the human data is
Thin. That is honest. The review acknowledges that direct human trials of FOXO4-DRI are preliminary. The human data it does marshal comes from studies of fisetin, a small-molecule flavonoid that modulates the same FOXO4 axis from a different angle. High-dose fisetin has been reported to reduce SASP and improve cognitive and physical measures in older adults. Fisetin is not FOXO4-DRI. It is a related-mechanism comparator and should be read as such.
Platform context
Peptidemodel's longevity ↗ target hosts five cards (Humanin, MOTS-c, Epithalon, Davunetide, ADNF-9) across mitochondrial, telomerase, and neurotrophic mechanisms. The anti-aging ↗ target hosts one (Epithalon again, via telomerase activation).
Senolysis is a different mechanism class. None of the cards on our platform currently model a senolytic peptide. The FOXO4-DRI review is a prompt to build one. The target (FOXO4-p53 complex) is defined, the sequence is public (from Baar et al., 2017), and the retro-inverso chemistry is well-characterized. A computational card is feasible.
What stays hard is the biology. Clearing senescent cells in a young-ish mouse is a different problem from clearing them in an 80-year-old with decades of accumulated tissue damage. The review makes the case that the brain is a good tissue to start with, because the brain's senescent cell burden is one of the pressure points in late-life cognitive decline. The next data to watch is not another review. It is the first controlled human trial of a senolytic peptide, which does not yet exist.